A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point.
A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point.
Pembrolizumab Combo May Benefit Elderly Metastatic NSCLC Cohort
